Biotech & Health Tech
FDA orders GLP-1 drugmakers to warn of rare eye disease
The FDA told GLP-1 drugmakers to update their product labels to reflect an increased risk of a rare eye condition that could lead to blindness. The agency said it was requiring companies to tack on ...
The FDA told GLP-1 drugmakers to update their product labels to reflect an increased risk of a rare eye condition that could lead to blindness. The agency said it was requiring companies to tack on ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗